Biotech Daily

Wednesday August 12, 2026

Daily news on ASX-listed biotechnology companies

*** ASX, BIOTECH DOWN: MICRO-X UP 11%; IMPEDIMED DOWN 17%**

*** PRO MEDICUS $23m ST LUKE'S VISAGE DEAL**

*** EBR UNAUDITED H1 REVENUE UP 30-FOLD TO $7.1m**

*** ANTERIS H1 REVENUE UP 28% TO $2.1m; LOSS UP 20% TO $73m**

*** SPARTAN: 'CIRCULAR RNA TO REVERSE ORGAN AGEING - TRIAL IN 2027'**

*** MCRI STEM CELL HEART VALVE TISSUE FOR HEART RESEARCH**

*** CONTROL BIONICS NEUROSTRIP AT APPLE, MICROSOFT SHOPS**

*** CLARIFICATION: LTR PHARMA**

*** CLINUVEL VLRX-L FLEXIBLE LIQUID INJECTABLE PEPTIDES**

*** RESONANCE: EXEMPT FROM QUARTERLY REPORTS**

*** INCANNEX RECEIVES $5.1m FEDERAL R&D TAX INCENTIVE**

*** ALTERITY WINS US ATH434 PATENT**

*** AVECHO BUYS-BACK 16m UNMARKETABLE PARCEL SHARES**

*** NIGHTINGALE TAKES 19% OF CONTROL BIONICS**

*** PHOENIX TAKES 16.5% OF CONTROL BIONICS**

MARKET REPORT

The Australian stock market fell 0.45 percent on Wednesday August 12, 2026, with the ASX200 down 41.2 points to 9,209.4 points. Eleven of the Biotech Daily Top 40 companies were up, 22 fell, and seven traded unchanged.

Micro-X was best, up 0.3 cents or 11.1 percent to 3.0 cents, with 339,390 shares traded. Syntara climbed 8.3 percent; Avita was up 7.0 percent; Emvision and Proteomics were up more than three percent; Actinogen, Curvebeam and Immutep rose two percent or more; 4D Medical, Cochlear, Dimerix and EBR were up one percent or more; with CSL and Resmed up by less than one percent.

Impedimed led the falls, down 0.1 cents or 16.7 percent to 0.5 cents, with 1.2 million shares traded. Amplia lost 6.7 percent; Optiscan and Starpharma were down more than five percent; Botanix and Imricor fell more than four percent; Aroa, Nanosonics, Resonance and Saluda were down three percent or more; Clinuvel, Paradigm, Prescient and Racura shed more than two percent; Clarity, Neuren and Nova Eye were down more than one percent; with Artrya, Mesoblast, Orthocell, Polynovo, Pro Medicus and Telix down by less than one percent.

PRO MEDICUS

Pro Medicus says it has a $23 million, seven-year contract with the Boise, Idaho-based St Luke's Health System for its Visage medical imaging systems.

Pro Medicus said St Luke's was "Idaho's largest private employer and not-for-profit healthcare provider" and its Boise Medical Center was "the flagship hospital of the health system, which spans 10 medical centres".

The company said the contract was based on a transactional licencing model and included its internet cloud-based Visage 7 Enterprise imaging platform with Viewer and Workflow to provide "a single, unified enterprise imaging platform" to St Luke's.

Pro Medicus said roll-out planning was expected to begin immediately, based on Visage's cloud-based implementation process, with implementation by April 2027.

Pro Medicus managing-director Dr Sam Hupert said St Luke's provided "outstanding, community-based care to patients across Southern Idaho, Eastern Oregon and Northern Nevada".

"They join an ever-growing list of Visage 7 clients to opt for our fully cloud-based platform, which, as a result of our cloud [picture archiving and communication system] strategy, is becoming the standard in the North American healthcare [information technology] market," Dr Hupert said.

"Our pipeline remains strong and spans all market segments from tier one academic medical centres through to large and mid-sized [integrated delivery networks] such as St Luke's as well as private imaging groups providing us with the largest addressable market of any offering in the market," Dr Hupert said.

Pro Medicus fell 66 cents or 0.4 percent to $181.67 with 249,464 shares traded.

EBR SYSTEMS

EBR says unaudited revenue for the six months to June 30, 2026 was up 29.5-fold to $US5,007,000 ($A7,095,000), compared to the prior corresponding period.

Last year, EBR said the US Food and Drug Administration cleared its Wise cardiac re-synchronization therapy for left ventricular endocardial pacing (BD: Apr 14, 2025).

In March, the company said it had maiden revenue of $US1,672,000 for the year to December 31, 2025, with loss up 30.4 percent to $US53,192,000 (BD: Mar 19, 2026).

Today, EBR said that six-month revenue from sales of its Wise cardiac re-synchronization therapy (CRT) leadless pacemaker device was $US4,936,000, with $US36,000 in surgical tool sales and $US35,000 from battery replacements.

The company said revenue reflected "continued commercial activity under the Wise market release and US commercial roll-out", with production and operating costs "higher as a result of increased purchases of long-lead-time inventory".

EBR said customer receipts were $US4,919,000 for the six months compared to $12,000 in the previous corresponding period, with a six-month cash burn up 49.5 percent to $US37,444,000, compared to the prior corresponding period.

EBR chief executive officer John McCutcheon said the company was "extremely pleased with this quarter on multiple fronts".

"Commercially, EBR surpassed its 100th commercial Wise implant, with multiple sites performing their first Wise implants and numerous more experienced sites continuing to treat patients with Wise," Mr McCutcheon said.

The company said diluted loss per share rose 23.7 percent to 73 US cents, with cash and cash equivalents of $US59,350,000 at June 30, 2026 compared to $US47,597,000 at June 30, 2025.

EBR was up half a cent or 1.75 percent to 29 cents with 4.3 million shares traded.

ANTERIS GLOBAL TECHNOLOGY CORP

Anteris says revenue for the six months to June 30, 2026 was up 28.0 percent to $US1,503,000 ($A2,130,000), with net loss after income tax up 20.2 percent to $US51,675,000 ($A73,212,000).

Anteris said it derived “revenue from the sale of regenerative tissue products … [and] such sales have historically been made principally to 4C Medical Technologies Inc and, in prior periods, to Lemaitre Vascular Inc, a distributor of medical products”.

Last year, the company said it would not renew its Adapt bovine tissue supply deal with 4C Medical Technologies Inc to produce medical devices (BD: Dec 2, 2025).

Today, Anteris did not disclose whether the regenerative tissue product sales included its Duravr transcatheter heart valve for aortic stenosis, which used its Adapt tissue and was the “significant focus” of its research and development investment.

Anteris said diluted loss per share fell 50.85 percent to 58 US cents, with cash and equivalents of $US257,385,000 at June 30, compared to $US28,438,000 the prior year.

Anteris was up 30 cents or 2.4 percent to $12.85.

SPARTAN THERAPEUTICS PTY LTD

Perth’s Spartan says it plans to begin a “world’s first” trial in 2027 to reverse the biological age of human organs and tissues using circular RNA (circRNA).

Spartan founder and chief scientific officer Dr Raymond Palmer told Biotech Daily that unlike messenger RNA which was a straight sequence of amino acids functioning as a code to typically manufacture a single protein, circular RNA was “a loop, meaning the machinery that runs along the amino acid sequence to make the protein cannot come off” and goes around the circular RNA continuously to produce “thousands of regenerative proteins … within hours”.

The company said its tissue reprogramming technology used circRNA “to directly deliver regenerative proteins among other clever molecules systemically into major organs and tissues throughout the body”.

Spartan said its tissue-reprogramming was “safer, cheaper and faster to market than partial cellular reprogramming, while acknowledging that both modalities may ultimately complement one another”.

The company said the first human “trial would assess the ability of the circRNA platform to restore more youthful function across the body with the explicit goal of keeping people healthy, functional and disease free for longer, but does not aim to make individuals appear 21 again”.

Dr Palmer told Biotech Daily that a phase I trial was expected to enrol 20 participants, with a 100-participant, up-to 12-month, phase II trial to follow, pending results.

Spartan said its focus was “on preventing age-related decline and placing age-related conditions into durable remission, thereby reducing the burden on families, the healthcare system and governments”.

The company said it held intellectual property covering circular RNA compositions and related constructs but did not disclose the jurisdictions of the patents not the durations.

Spartan said it was conducting pre-clinical work to progress toward a systemic human study in 2027, which was “first-of-its-kind aimed at multi-organ age reversal”.

The company said it would release additional trial design, regulatory pathway and clinical site details subject to ethics and regulatory approvals.

Dr Palmer said with falling birth rates and a growing older population, healthcare costs would be unsustainable and preventing aging was the only feasible long-term pathway.

Spartan is a private company.

MURDOCH CHILDREN'S RESEARCH INSTITUTE

Murdoch Children's Research Institute (MCRI) says it has developed human heart valve tissues from stem cells for advancing treatments for childhood heart diseases.
MCRI said the "world-first discovery" had produced laboratory-grown heart valve tissues that "closely resemble those in the human body", and the platform could model inflammatory valve disease, an underlying precursor to rheumatic heart disease.
The Institute said "the breakthrough would help accelerate regenerative approaches for repairing damaged valves in children and adults".
MCRI said the research, titled 'Human heart valve-like tissues from pluripotent stem cells with enhanced maturation recapitulate inflammatory valve disease' was published in Cell Stem Cell, with the full article was available at: https://bit.ly/3SaeCRo.
The Institute said the research was conducted with the University of Melbourne, Baker Heart and Diabetes Institute, Peter MacCallum Cancer Centre, Monash University, the Queensland Institute of Medical Research (QIMR) Berghofer, Olivia Newton John Cancer Research Center and the Royal Children's Hospital.
MCRI researcher Dr Holly Voges said there were no treatments to reverse the damage caused by heart valve disease.
"Most patients depend on valve replacement surgery, which has significant limitations, including a high risk of blood clots and, for children, the likelihood of needing multiple procedures over their lifetime," Dr Voges said.
"By creating heart valve tissues that mimic the molecular features of a human version we can now test and advance new treatments at scale," Dr Voges said.
"When exposed to inflammatory proteins linked to rheumatic heart disease discovered in previous studies, we found the engineered stem cell tissues became stiffer and showed bio-markers consistent with diseased human valves," Dr Voges said.

CONTROL BIONICS

Control Bionics says its Neurostrip application is available at Apple and Microsoft shops, making its wearable surface electro-myo-graphy (EMG) platform more accessible.
Control Bionics said the application was free-to-download and allowed clinicians, physiotherapists, researchers and sporting organizations to connect and use Neurostrip with existing devices, without requiring custom software installation.
The company said Neurostrip was its wearable surface EMG sensor platform, designed for use in elite sports performance, clinical rehabilitation and research settings.
Control Bionics said Neurostrip hardware was supplied in markets where it held the applicable regulatory registrations, with the application launch building "on growing customer engagement across Australia, New Zealand, the US, Europe and Japan".
The company Neurostrip was subject to US Food and Drug Administration registration and listing, with regulatory applications progressing in Australia and the European Union.
Control Bionics managing-director Jeremy Steele said making Neurostrip available through major retailers removed "friction for customers and provides a more scalable way to distribute and support the platform globally".
"It expands access to our technology and supports our strategy to grow recurring software and subscription revenue," Mr Steele said.
"Our customers can now find and use our software the same way they access everything else on their devices," Mr Steele said.
"It opens the platform to a far wider audience than we could reach through direct distribution alone," Mr Steele said.
Control Bionics was unchanged at 6.2 cents.

CLARIFICATION: LTR PHARMA

Last night's edition had the headline: LTR 'Spontan 68% Erectile Dysfunction Response', which was accurate but did not give the company's most important information.
LTR executive chair Lee Rodne told Biotech Daily there were specific sub-groups within the total of 147 patients who benefited from Spontan and what was most important was that 42 of 45 men (93%) seeking greater convenience and spontaneity, reported "improved erectile hardness and/or achieving penetration with Spontan" along with 56 of 87 men (64%) in the difficult-to-treat post-prostatectomy group, as well as 58 of 102 men (57%) who had previously reported inadequate efficacy with oral PDE5 inhibitors.
The headline should have read: 'LTR 'Spontan 93% Erectile Dysfunction Response; 64% Post-Prostatectomy'
No sub-editors were hurt in making this clarification.
LTR was up half a cent or one percent to 52 cents.

CLINUVEL PHARMACEUTICALS

Clinuvel says it has flexible liquid dose formulations for its injectable peptide VLRX-L, which show "the greatest potential for further development".
Clinuvel said the initial focus of the VLRX-L platform was melano-cortins, peptides which bind to the five melanocortin receptors in the body, known to affect melanogenesis, inflammation, libido and other functions.
Earlier this year, the company said it began an in-vitro study of its liquid injectable peptide VLRX-L for controlled-release of its melano-cortin-based drugs (BD: Jan 18, 2026).
Today, Clinuvel said it was developing VLRX-L "for greater individualization of patient treatment, titrating doses or adjusting for specific patient populations".
The company said a pre-clinical study with the four candidate VLRX-L formulations confirmed in-vitro results and that one candidate formulation showing "a superior release profile over the targeted peptide delivery window, with lower peak plasma levels and drug detected over the delivery period".
Clinuvel said based on the pre-clinical results it was "refining the candidate formulation, intending to conduct a further pre-clinical study" by April 2027.
Clinuvel chief scientific officer Dr Dennis Wright said the company was "looking for an indication that our candidate formulations could control the release of a peptide in a pre-clinical model [which had] been demonstrated".
Clinuvel fell 21 cents or 2.2 percent to $9.50.

RESONANCE HEALTH

Resonance says it has sufficient net operating cash flow for the ASX to lift its requirement to lodge Appendix 4C quarterly reports, effective immediately.
Resonance said it had positive operating cash flow in all four three-month periods for the year to June 30, 2026, full-year net positive operating cash inflow of $2.9 million and a net cash position of $2.3 million at June 30, 2026, "with group revenue having grown from $4 million in 2022-'23 to recent 2025-'26 guidance of $16 million".
Resonance managing-director Andrew Harrison said the decision reflected "where the business now sits, operating cash flow positive in every quarter of 2025-'26, a growing net cash position, and revenue up from … 2022-'23 to recent 2025-'26 guidance".
"Shareholders will continue to get the numbers that matter, at the half year, at the full year, and immediately in accordance with our continuous disclosure obligations," he said.
Resonance fell 0.2 cents or 3.5 percent to 5.5 cents.

INCANNEX HEALTHCARE

Incannex says it has received $5,102,788 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive program.
Incannex said the incentive related to research and development for the year to June 30, 2025, followed approval of its overseas findings and amendment to its 2024-'25 income tax return and took its total tax incentive for the year to more than $11.2 million.
On the Nasdaq, Incannex fell 3.0 US cents (4.25 Australian cents) or 0.9 percent to $US3.20 ($A4.53) with 97,399 shares traded.

ALTERITY THERAPEUTICS

Alterity says the US Patent and Trademark Office has granted a composition of matter patent for its oral ATH434 treatment for neurodegenerative diseases.
Alterity said the patent, titled 'Crystalline Form, and Process for its Production' would protect its intellectual property related to composition of matter of ATH434 mesylate as well as methods for treating neurological conditions using it until "at least 2045".
Alterity managing-director Dr David Stamler said "with protection to at least 2045, this patent extends the commercial life and revenue potential for ATH434 in [multiple system atrophy], if approved, as we prepare to initiate phase III trial activities by year-end 2026".
Alterity was up two cents or 3.7 percent to 56 cents with 1.25 million shares traded.

AVECHO BIOTECHNOLOGY

Avecho says it has bought back and sold 15,744,635 shares, held by 2,113 shareholders, in an unmarketable parcel facility.
Earlier this year, Avecho said it had established an unmarketable parcel facility for holders of shares worth less than $500, or 41,666 shares at the last closing price of 1.2 cents, with CPS Capital Group to sell the bought-back shares (BD: May 27, 2026).
Today, the company said about 37 percent of eligible unmarketable parcel holders sold their holdings under the facility, with the number of shareholders on the register reduced from 5,751 shareholders to 3,761 shareholders.
Avecho did not disclose the average sale price of the bought-back shares but said "shareholders whose shares were sold under the facility would have their proceeds remitted to them and would be sent documentation advising them of the number of shares sold and the amount of proceeds remitted".
Avecho fell 0.1 cents or 4.8 percent to two cents with 5.3 million shares traded.

CONTROL BIONICS

Nightingale Partners says it has increased its substantial shareholding in Control Bionics from 75,516,916 shares (18.33%) to 104,069,518 shares (19.16%).
In a shareholder notice signed by company secretary David Falk, the Level 3, 22 Market Street, Sydney-based Nightingale said it bought 21,769,753 shares in a placement on August 12, 2026 for $1,632,731, or 7.5 cents a share, and between June 12 and August 7, 2026 bought 6,782,849 shares for $529,251, or 7.8 cents a share.
Earlier this year, Control Bionics said it had commitments to raise $9,500,000 at 7.5 cents a share, a 14.5 percent discount to the five-day volume weighted average price, in a placement, and later said it raised $256,000 of a hoped-or $500,000 in a share purchase plan at the same price (BD: Jun 25, Jul 21, 2026).

CONTROL BIONICS

Phoenix Development Fund says it has increased its substantial shareholding in Control Bionics from 70,194,769 shares (16.19%) to 89,384,718 shares (16.45%).

In a notice signed by company secretary David Falk, the Level 3, 22 Market Street, Sydney-based Pheonix said that on August 12, 2026 it bought 19,189,949 shares in a placement for $1,439,246, or 7.5 cents a share (see above).